14.82 +0.10 (0.66%)
Pre-Market: 8:29AM EDT
|Bid||14.80 x 2300|
|Ask||14.83 x 500|
|Day's Range||14.58 - 14.97|
|52 Week Range||14.30 - 44.42|
|PE Ratio (TTM)||-2.41|
|Dividend & Yield||1.10 (7.38%)|
|1y Target Est||N/A|
Kare Schultz will start his new post as chief executive of Israel's Teva Pharmaceutical Industries by the end of October, the Calcalist financial newspaper reported on Tuesday. A Teva spokesman, asked about the Israeli news report, said the company does not comment on market rumours. Teva poached Schultz from Denmark's Lundbeck in September, handing the drugs industry veteran the urgent task of convincing investors of the struggling Israeli firm's future.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for fremanezumab, an anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibody for the preventive treatment of migraine. TEVA Chief Scientific Officer Michael Hayden commented, "The BLA submission for fremanezumab marks a very important milestone for the migraine community [...] There have been few therapeutic innovations for migraine patients in over 25 years. If approved, fremanezumab will be among the first to enter the market in a new class of drugs for the preventive treatment of migraine.
BDSI further said that additional terms of the settlement agreement are confidential and that the agreement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice. A Teva spokeswoman confirmed the settlement agreement and launch date.
The September 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
With another challenge cropping up for Teva (TEVA) in the form of earlier-than-expected generic competition for the 40 mg dose of Copaxone, here is a look at 5 drug stocks that look better-positioned.
BT Group PLC (BT), Cardinal Health Inc. (CAH), Teva Pharmaceutical Industries Ltd (TEVA), and Chipotle Mexican Grill Inc. (CMG) have declined to their respective three-year lows.
The FDA approval of Mylan's (MYL) generic version of Teva's Copaxone was the main news this week. Allergan was also in the headlines related to its deal with the Saint Regis Mohawk Tribe.
Lilly (LLY) has received a favorable ruling from the U.S. PTO in a dispute related to vitamin regimen patent on its key cancer drug, Alimta.
Teva's blockbuster multiple sclerosis treatment Copaxone will face additional generic competition in Europe, just two days after Mylan NV won U.S. approval to sell cheaper versions of the medicine in the world's largest market. Mylan's European partner, Synthon, and Alvogen said on Thursday they had received decentralized European approval for a 40 milligram dose of glatiramer acetate, as Copaxone is known generically. Nearly 20 percent of total sales for Teva Pharmaceutical Industries comes from branded Copaxone.
Morgan Stanley analysts downgraded shares of Celgene over concerns of generic drug pressures. Those concerns are not warranted just yet and Celgene is not a sell, Jim Cramer reasoned.
The CNBC IQ100 index is beating the broader market over one year up 22%. Today's leaders include Motorola Solutions, Teva Pharma, GM, Metlife and Prudential.